Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Pilot Study of SGT-53 With Carboplatin and Pembrolizumab in Metastatic Triple Negative Inflammatory Breast Cancer

NCT05093387 is registered in ClinicalTrials.gov with Northwestern University as lead sponsor.

NCT NCT05093387
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05093387 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Pilot Study of SGT-53 With Carboplatin and Pembrolizumab in Metastatic Triple Negative Inflammatory Breast Cancer
Lead sponsor
Northwestern University
Phase
Phase 1
Overall status
Withdrawn
Start date
November 10, 2022
Completion date
November 10, 2022
Enrollment
0 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

anatomic stage iv breast cancer ajcc v8, breast inflammatory carcinoma, metastatic triple-negative breast carcinoma, prognostic stage iv breast cancer ajcc v8